3
Laboratory forThrombosis Research, IRC, KU Leuven, Campus Kortrijk, Belgium
,
Hans Deckmyn
3
Laboratory forThrombosis Research, IRC, KU Leuven, Campus Kortrijk, Belgium
,
Marc Forestier
1
Department of Medicine, Laboratory for Thrombosis Research, Kantonsspital Baden, Switzerland
,
Jürg H. Beer
1
Department of Medicine, Laboratory for Thrombosis Research, Kantonsspital Baden, Switzerland
› Author AffiliationsFinancial support: Supported in part by the Swiss National Science Foundation, Grant-No. 32–59449.99 (JHB) Grant-No. 320080–104202 and the Swiss Heart Foundation (JHB).
We studied the inhibition of platelet microparticle (MP) formation and thrombin generation under high shear forces. We hypothesized that an inhibitor of the GPIbα-von Willebrand factor (vWF) interaction would be more effective in suppressing MP formation and thrombin generation than GPIIb/IIIa inhibitors. Platelet-rich plasma (PRP) anticoagulated with PPACK (D-Phe-Pro-Arg chloromethyl ketone) was exposed in a coneand-plate viscometer (shear: 5,000 s−1 for5 min) in the presence of antagonists to GPIbα (the monoclonal antibody [Mab] Ib-23) or to GPIIb/IIIa (abciximab, tirofiban, eptifibatide) at their IC90 determined in platelet aggregometry with ristocetin or ADP, respectively. We used double labeling (CD41-PE and annexin-V-FITC) for flow cytometric detection of MP and their aminophospholipid exposure. Thrombin generation was measured using PRP prepared fromACD anticoagulated blood. About 40% of the thrombin generation was found to be mediated by the MP fraction of the PRP. Blockade of GPIbα with Mab Ib-23 reduced MP formation and thrombin generation by 50%, and was more effective than any GPIIb/IIIa antagonist. The combination of Mab Ib-23 with one of the GPIIb/IIIa inhibitors further reduced the MP formation to ∼30%. The antibody also partially inhibited thrombin induced platelet aggregation. Epitope mapping suggested that Mab Ib-23 binds between the amino acids 201 and 268 of GPIbα, explaining the interference with vWF and thrombin interaction. In contrast to the commonly used GPIIb/IIIa antagonists, the blockade of GPIbα with Mab Ib-23 effectively reduces the prothrombotic MP generation and thrombin formation at shear rates typically found in arterial stenoses.
Footnote: Parts of this work were presented orally at the International Congress of Thrombosis and Hemostasis in Birmingham (2003), at the Meeting of the Swiss Society of Hematology in Basel, and as poster at the Meeting of the American Society of Hematology in San Diego (2003). Abstracts were published in Blood (2003); 102: 804a and in the Supplement to Thrombosis and Heamostasis, July 2003: OC465.
References
1
Mallat Z,
Benamer H,
Hugel B.
et al. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000; 101: 841-3.
3
Morel O,
Hugel B,
Jesel L.
et al. Circulating procoagulant microparticles and soluble GPV in myocardial infarction treated by primary percutaneous transluminal coronary angioplasty. A possible role for GPIIb-IIIa antagonists. J Thromb Haemost 2004; 02: 1118-26.
5
Miyamoto S,
Marcinkiewicz C,
Edmunds Jr LH.
et al. Measurement of platelet microparticles during cardiopulmonary bypass by means of captured ELISA for GPIIb/IIIa. Thromb Haemost 1998; 80: 225-30.
7
Morel O,
Hugel B,
Jesel L.
et al. Sustained elevated amounts of circulating procoagulant membrane microparticles and soluble GPV after acute myocardial infarction in diabetes mellitus. Thromb Haemost 2004; 91: 345-53.
9
Andoh A,
Tsujikawa T,
Hata K.
et al. Elevated circulating platelet-derived microparticles in patients with active inflammatory bowel disease. Am J Gastroenterol 2005; 100: 2042-8.
10
Lee DH,
Warkentin TE,
Denomme GA.
et al. A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry. Br J Haematol 1996; 95: 724-31.
11
Miyazaki Y,
Nomura S,
Miyake T.
et al. High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles. Blood 1996; 88: 3456-64.
12
Nomura S,
Tandon NN,
Nakamura T.
et al. Highshear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis 2001; 158: 277-87.
13
Morel O,
Toti F,
Hugel B.
et al. Cellular microparticles: a disseminated storage pool of bioactive vascular effectors. Curr Opin Hematol 2004; 11: 156-64.
16
Sims PJ,
Wiedmer T,
Esmon CT.
et al. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J Biol Chem 1989; 264: 17049-57.
18
Goto S,
Tamura N,
Li M.
et al. Different effects of various anti-GPIIb-IIIa agents on shear-induced platelet activation and expression of procoagulant activity. J Thromb Haemost 2003; 01: 2022-30.
19
Lincoff AM,
Califf RM,
Van de Werf F.
et al. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. J Am Med Assoc 2002; 288: 2130-5.
21
Wu D,
Meiring M,
Kotze HF.
et al. Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. Arterioscler Thromb Vasc Biol 2002; 22: 323-8.
22
Pontiggia L,
Steiner B,
Beer J.
50% of the thrombin generation under high shear rate is mediated by platelet microparticles and can be inhibited by a monoclonal antibody against GPIb. Blood. 2003 804. a (Abstract 2979).
24
Genewein U,
Haeberli A,
Straub P.
et al. Rebound after cessation of oral anticoagulant therapy: The biochemical evidence. Brit J Haematol 1996; 92: 479-85.
25
Goding JW.
Monoclonal Antibodies: Principles and Practice. Production and Application of Monoclonal Antibodies in Cell Biology, Biochemistry and Immunology. 2nd ed. London: Academic Press Limited; 1986
26
Cauwenberghs N,
Vanhoorelbeke K,
Vauterin S.
et al. Epitope mapping of inhibitory antibodies against platelet glycoprotein Ibalpha reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Ibalpha. Blood 2001; 98: 652-60.
27
Ulrichts H,
Vanhoorelbeke K,
Cauwenberghs S.
et al. von Willebrand factor but not alpha-thrombin binding to platelet glycoprotein Ibalpha is influenced by the HPA-2 polymorphism. Arterioscler Thromb Vasc Biol 2003; 23: 1302-7.
28
Holme PA,
Orvim U,
Hamers MJ.
et al. Shear-induced platelet activation and platelet microparticle formation at blood flow conditions as in arteries with a severe stenosis. Arterioscler Thromb Vasc Biol 1997; 17: 646-53.
29
Greve B,
Beller C,
Cassens U.
et al. High-grade loss of leukocytes and hematopoietic progenitor cells caused by erythrocyte-lysing procedures for flow cytometric analyses. J Hematother Stem Cell Res 2003; 12: 321-30.
33
Reininger AJ,
Heijnen HF,
Schumann H.
et al. Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress. Blood 2006; 107: 3537-45.
34
Kereiakes DJ,
Lorenz T,
Young JJ.
et al. Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban. J Thromb Thrombolysis 2001; 12: 123-7.
35
Cauwenberghs N,
Meiring M,
Vauterin S.
et al. Antithrombotic effect of platelet glycoprotein Ibblocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler Thromb Vasc Biol 2000; 20: 1347-53.
37
Ilveskero S,
Lassila R.
Abciximab inhibits procoagulant activity but not the release reaction upon collagen- or clot-adherent platelets. J Thromb Haemost 2003; 01: 805-13.
